6th Annual MarketsandMarkets

Real-World Evidence and Life Sciences Analytics Conference

16th - 17th October 2023

Hampton Inn by Hilton Boston Seaport District

Avail Your Ticket Avail
Your Ticket
Become A Sponsor Become
A Sponsor
Become A Speaker Become
A Speaker

EVENT OVERVIEW

To Pioneer the Integration of RWE/RWD into Experimental and Regulatory Approach

MarketsandMarkets is proud to announce the 6th Annual Real-World Evidence and Life Sciences Conference to be held on October 16th - 17th, 2023 at Hampton Inn by Hilton Boston Seaport District.

Real-world data and real-world evidence are poised to keep making strides in 2023.
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions.

Shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes. Telemedicine and virtual care may also provoke a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.

Additionally with the new guidance by the FDA around data quality and data standards, the stakeholders are seeking to learn its long term impact and safety surveillance. This conference will focus on above said significant points and hold discussions on the best practices adopted by various stakeholders with a key takeaway being better decision making.

WHAT TO EXPECT

  • Regulatory view around data quality & data standards.
  • Leveraging RWE for improving market access.
  • The adoption & role of AI & ML in clinical trials.
  • Real-world evidence & Digital Health - The expanded role of RWE for digital health.
  • Panel Discussion on lessons learned from the recent results of the FDA’s
    pilot program RCT DUPLICATE.
  • Real-World Data & Advanced Analytics.
  • RWE to inform decision making process in rare diseases where there is lack of evidence.

  • Learn about the recent trends and advancements in Real-World Evidence Generation
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence, Real-World Data, Health Economics & Outcomes Research- HEOR, Market Access/Value Access, Clinical Outcomes, Clinical Development & research, Clinical trial and others

Expression #1 of SELECT list is not in GROUP BY clause and contains nonaggregated column 'cnceventswithcrm.s.id' which is not functionally dependent on columns in GROUP BY clause; this is incompatible with sql_mode=only_full_group_by